Prognostic impact of EGFR expression and immunohistochemistry-based "molecular classification" in bladder cancer.

Recent genomic studies emphasize the necessity of molecular classification to reflect diverse clinical and pathological characteristics of bladder cancer. Immunohistochemically bladder cancer can be classified into molecular subtypes, including basal, luminal, and p53-like subtypes. Epidermal growth factor receptor (EGFR) is frequently expressed in basal-type bladder cancers and is associated with poor prognosis.

Diagnostic models for predicting malignancy in thyroid nodules classified as Bethesda Category III in an endemic region.

Background: This study aims to develop a diagnostic model to help physicians determine whether thyroid nodules categorized as atypia of undetermined significance (AUS) in category III of the Bethesda system are benign or malignant preoperatively. To create a diagnostic model for predicting thyroid nodules' benign or malignant with AUS cytology based on clinical, ultrasonographic, and cytopathological findings.

Methods: This is a retrospective cohort study involving patients (>19) at risk of thyroid cancer who had thyroidectomy after an AUS cytology.